Custom service
Antimicrobial Cyclic Peptide Development
Develop cyclic antimicrobial peptides with stability and selectivity testing
Antimicrobial Cyclic Peptide Development supports programmes that develop cyclic antimicrobial peptides with stability and selectivity testing. In a typical engagement we plan the cyclotin and AMP motif engineering route first, confirm compatibility with selectivity (hemolysis) profiling, and release lead cyclic AMP with activity and selectivity report on a 6–10 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep cyclotin and AMP motif engineering as the primary option and hold selectivity (hemolysis) profiling in reserve, so that scale-up never depends on an unproven step.
Gram-positive and Gram-negative spectrum expansion
Anti-biofilm peptide development
Clinical candidate development past lead stage
Cycles whose ring size is known to be geometrically uncloseable
Cyclic products are released against connectivity, not mass alone. MS/MS fragmentation confirms the ring closure, and where multiple topologies are possible the target isomer is isolated and its ratio reported. Protease-stability data are available as an add-on.
Service Highlights
- Cyclotin and AMP motif engineering as the default route, with selectivity (hemolysis) profiling held as a proven fallback
- Protease-stability screening worked into the design where the application requires it
- Cyclization strategy (head-to-tail, disulfide, lactam, thioether) chosen from a feasibility screen, not fixed by habit
- Analytical confirmation of every intermediate before the final release
- Cyclic/linear and topological isomers separated and reported, with the target isomer identified by MS/MS
- Lead cyclic AMP with activity and selectivity report delivered with a complete conjugation or synthesis certificate
How the work runs
Precursor design
Linear precursor, cyclization sites and protecting strategy are designed around the Antimicrobial Cyclic Peptide Development ring size.
Linear assembly
The precursor chain is assembled with Fmoc chemistry and cyclotin and AMP motif engineering where relevant.
Cyclization
Ring closure is executed by selectivity (hemolysis) profiling under screened dilution and activation conditions.
Isomer separation
RP-HPLC resolves cyclic/linear and topological isomers; the target isomer is collected.
Characterization
Connectivity, purity and identity are confirmed by MS/MS and HPLC against the specification.
Release
Lead cyclic AMP with activity and selectivity report is documented and released after QC sign-off.
Specifications & timeline
- Turnaround
- 6–10 weeks
- Typical scale
- 1 – 200 mg cyclic peptide
- Chemistry options
- cyclotin and AMP motif engineering; selectivity (hemolysis) profiling; protease-stability screening
- Deliverable
- Lead cyclic AMP with activity and selectivity report
- QC package
- HPLC purity, MS/MS connectivity proof, isomer ratio, DMSO solubility
- Shipping
- Ambient with desiccant; blue ice for sensitive motifs
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.